Geneoscopy said the US Centers for Medicare and Medicaid Services expanded coverage for its ColoSense stool-based RNA test within the national coverage determination for colorectal cancer screening. The company noted the updated framework supports future RNA-based assays and aligns with FDA-authorized use, including a recommended three-year testing interval. ColoSense was reported to show 93% sensitivity for colorectal cancer in average-risk patients and 45% sensitivity for advanced adenomas, with 100% sensitivity for stage I cancer. Geneoscopy also highlighted that it qualitatively detects colorectal neoplasia-associated RNA markers alongside occult hemoglobin in stool. Geneoscopy said it will work with Labcorp to expand access through its nationwide network, extending the reach of RNA-based diagnostics beyond clinical trials into routine screening infrastructure.